Skip to main content

Advertisement

Fig. 2 | Cancer Cell International

Fig. 2

From: MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

Fig. 2

MLL3/KMT2C expression profile between CML patients and healthy controls. a MLL3/KMT2C expression is upregulated in CML patients compared to control samples (45 CML patients and 18 control samples, Mann–Whitney test, p = 0.0004). b MLL3/KMT2C expression profile frequency among different stages of CML. The median value of MLL3/KMT2C expression was used as the cut-off to dichotomize CML patients in “low” and “high” expression groups. The high expression of MLL3/KMT2C was more frequent in the chronic phase (Chi square goodness of fit test, p = 0.0212). c MLL3/KMT2C expression is also upregulated in 76 CML patients compared to 73 control samples from the MILE study group (Microarray probe 1557158_at, Mann–Whitney test, p = 0.0338)

Back to article page